Aarti Drugs Q4FY 22 consolidated revenue grew by 39 per cent YoY
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
The plan is to advance innovative therapies to drug-resistant cancers
Saumen is a postgraduate in management from IIM, Ahmedabad and an executive fellow in management from ISB, Hyderabad
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
Formula attenuates 99% of 365 coronaviruses in computer models
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
At an affordable price, a researcher can process fresh samples of 10,000 cells immediately with a stable stopping point within two hours, simplifying sample management at the laboratory and limiting transcriptional changes
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Subscribe To Our Newsletter & Stay Updated